Dr. Scholz on Significance of ARAMIS Trial in CRPC

Interview by OncLiveTV

Mark Scholz, MD Interviews with OncLive at ASCO GU 2019

In his recent interview with OncLiveTv, Dr. Scholz discusses the importance of timely treatment for hormone resistant prostate cancer: “We still need to raise awareness that men need to start treatment at the first sign of hormone resistance.” 

“Trials like [the ARAMIS trial] help bring attention to the fact that we need to change the way we’re managing the patients too.  They need to be managed much more aggressively.” Darolutamide, apalutamide, and Xtandi, provide effective, relatively harmless opportunities to delay metastasis in patients with hormone resistant prostate cancer.

Leave a Reply

Your email address will not be published.